GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

“If your itching is caused by a liver problem, there won’t be a skin rash or an insect bite,” the Liver Foundation says. The ...

Lisa Woodcock's initial instinct when she first developed severe itching all over her body was to blame an allergic reaction ...

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary ...

The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019.